Table 2.
Summary of studies about premedication with pronase for visualization of the mucosa during advanced endoscopy
| Examination | Ref. | Year | Study design | Premedication group (n) | Mucosal visibility |
| Chromoendoscopy | Fujii et al[8] | 1998 | Prospective | A: DMPS (34) B: DMPS + SB (32) C: DMPS + SB + pronase (34) | C > A, B |
| NBI endoscopy | Cha et al[17] | 2014 | Prospective | A: Pronase + SB (28) B: Simethicone (27) | A > B |
| ME-NBI | Kim et al[7] | 2015 | Prospective | A: Simethicone + SB + pronase (71) B: Simethicone (72) | A > B |
| EUS | Sakai et al[24] | 2003 | Prospective | A: DMPS (29) B: DMPS + SB (29) C: DMPS + SB + pronase (29) | C > A, B |
| Han et al[25] | 2011 | Prospective | A: Saline (60) B: Pronase + SB (62) C: Pronase + SB + simethicone (61) | B > A > C |
NBI: Narrow-band imaging; ME-NBI: Magnifying endoscopy with narrow-band imaging; EUS: Endoscopic ultrasonography; DMPS: Dimethylpolysiloxane; SB: Sodium bicarbonate.